Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The article describes step wise directed differentiation of induced pluripotent stem cells to three-dimensional whole lung organoids containing both proximal and distal epithelial lung cells along with mesenchyme.

Abstract

Human lung development and disease has been difficult to study due to the lack of biologically relevant in vitro model systems. Human induced pluripotent stem cells (hiPSCs) can be differentiated stepwise into 3D multicellular lung organoids, made of both epithelial and mesenchymal cell populations. We recapitulate embryonic developmental cues by temporally introducing a variety of growth factors and small molecules to efficiently generate definitive endoderm, anterior foregut endoderm, and subsequently lung progenitor cells. These cells are then embedded in growth factor reduced (GFR)-basement membrane matrix medium, allowing them to spontaneously develop into 3D lung organoids in response to external growth factors. These whole lung organoids (WLO) undergo early lung developmental stages including branching morphogenesis and maturation after exposure to dexamethasone, cyclic AMP and isobutylxanthine. WLOs possess airway epithelial cells expressing the markers KRT5 (basal), SCGB3A2 (club) and MUC5AC (goblet) as well as alveolar epithelial cells expressing HOPX (alveolar type I) and SP-C (alveolar type II). Mesenchymal cells are also present, including smooth muscle actin (SMA), and platelet-derived growth factor receptor A (PDGFRα). iPSC derived WLOs can be maintained in 3D culture conditions for many months and can be sorted for surface markers to purify a specific cell population. iPSC derived WLOs can also be utilized to study human lung development, including signaling between the lung epithelium and mesenchyme, to model genetic mutations on human lung cell function and development, and to determine the cytotoxicity of infective agents.

Introduction

The lung is a complicated, heterogeneous, dynamic organ that develops in six distinct stages - embryonic, pseudoglandular, canalicular, saccular, alveolar, and microvascular maturation1,2. The latter two phases occur pre and postnatally in human development while the first four stages occur exclusively during fetal development unless preterm birth occurs3. The embryonic phase begins in the endodermal germ layer and concludes with the budding of the trachea and lung buds. Lung development occurs in part via signaling between the epithelial and mesenchymal cells4. ....

Protocol

This study protocol was approved by the Institutional Review Board of UCSD's Human Research Protections Program (181180).

1. Definitive endoderm induction from induced pluripotent stem cells (Day 1 - 3)

  1. Slowly thaw growth factor reduced (GFR)-basement membrane (BM) matrix medium on ice 30 minutes prior to use. In cold DMEM/F12, mixture, dilute the GFR BM matrix medium 1:1 such that it constitutes 50% of this medium. Place P1000 pipette tips in the freezer to chill prior to use........

Representative Results

24 hours after plating, day 1, iPSCs should be 50%-90% confluent. On day 2, DE should be 90%-95% confluent. During DE induction, it is common to observe significant cell death on day 4 but attached cells will retain a compact cobblestone morphology (Figure 2b). Discontinue differentiation if the majority of adherent cells detach and consider shortening exposure to DE media with activin A by 6-12 h. During AFE induction, cell death is minimal, and cells remain adherent, but will appear smalle.......

Discussion

The successful differentiation of 3D whole lung organoids (WLO) relies on a multi-step, 6-week protocol with attention to detail, including time of exposure to growth factors and small molecules, cellular density after passaging, and the quality of hiPSCs. For troubleshooting, see Table 2. hiPSCs should be approximately 70%-80% confluent, with less than 5% spontaneous differentiation prior to dissociation. This protocol calls for "mTeSR plus" medium; however,  plain "mTeSR" medium.......

Acknowledgements

This research was supported by the California Institute for Regenerative Medicine (CIRM)  (DISC2-COVID19-12022).

....

Materials

NameCompanyCatalog NumberComments
Cell Culture
12 well platesCorning3512
12-well inserts, 0.4um, translucentVWR10769-208
2-mercaptoethanolSigma-AldrichM3148
AccutaseInnovative Cell TechAT104
ascorbic acidSigmaA4544
B27 without retinoic acidThermoFisher12587010
Bovine serum albumin (BSA) Fraction V, 7.5% solutionGibco15260-037
DispaseStemCellTech7913
DMEM/F12Gibco10565042
FBSGibco10082139
GlutamaxLife Technologies35050061
Ham’s F12Invitrogen11765-054
HEPESGibco15630-080
Iscove’s Modified Dulbecco’s Medium (IMDM) + GlutamaxInvitrogen31980030
Knockout Serum Replacement (KSR)Life Technologies10828028
MatrigelCorning354230
MonothioglycerolSigmaM6145
mTeSR plus Kit (10/case)Stem Cell Tech5825
N2ThermoFisher17502048
NEAALife Technologies11140050
Pen/strepLonza17-602F
ReleSRStem Cell Tech5872
RPMI1640 + GlutamaxLife Technologies12633012
TrypLEGibco12605-028
Y-27632 (Rock Inhibitor)R&D Systems1254/1
Growth Factors/Small Molecules
Activin AR&D Systems338-AC
All-trans retinoic acid (RA)Sigma-AldrichR2625
BMP4R&D Systems314-BP/CF
Br-cAMPSigma-AldrichB5386
CHIR99021Abcamab120890
DexamethasoneSigma-AldrichD4902
DorsomorphinR&D Systems3093
EGFR&D Systems236-EG
FGF10R&D Systems345-FG/CF
FGF7R&D Systems251-KG/CF
IBMX (3-Isobtyl-1-methylxanthine)Sigma-AldrichI5879
SB431542R&D Systems1614
VEGF/PIGFR&D Systems297-VP/CF
Primary antibodiesDilution rate
CXCR4-PER&D SystemsFAB170P1:200 (F)
HOPXSanta Cruz Biotechsc-3987030.180555556
HTII-280Terrace BiotechTB-27AHT2-2800.145833333
KRT5Abcamab526350.180555556
NKX2-1Abcamab760130.25
NKX2-1-APCLS-BIOLS-C2644371:1000 (F)
proSPCAbcamab408710.215277778
SCGB3A2Abcamab1818530.25
SOX2InvitrogenMA1-0140.180555556
SOX9R&D SystemsAF30750.180555556
SPB (mature)7 Hills486041: 1500 (F) 1:500 (W)a
SPC (mature)LS BioLS-B91611:100 (F); 1:500 (W) a

References

  1. Ten Have-Opbroek, A. A. Lung development in the mouse embryo. Experimental Lung Research. 17 (2), 111-130 (1991).
  2. Perl, A. K., Whitsett, J. A. Molecular mechanisms controlling lung morphogenesis. Clinical Genetics. 56....

Explore More Articles

3D Whole Lung OrganoidsInduced Pluripotent Stem CellsLung Developmental BiologyLung Disease ModelingPrimary Human Lung TissueCryopreservationGenetic ManipulationDefinitive Endoderm InductionROCK InhibitorGFR Basement Membrane Matrix

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved